Skip to main content
Premium Trial:

Request an Annual Quote

Accelr8's Stock Plummets after BD Declines Option on Bacterial Dx Tech

NEW YORK (GenomeWeb News) – Shares in Accelr8 plummeted nearly 30 percent today following news that Becton Dickinson has declined an option to license the company's rapid bacterial diagnostic system.

BD advised the company that it would decline an exclusive license option to the technology associated with an 18-month testing agreement it inked with Accelr8 in April 2008.

The option would have provided an exclusive license to BD to develop and sell a clinical diagnostic system for infectious diseases based on the platform, with Accelr8 retaining rights to all other commercial applications.

Accelr8 said that its technology, called BACcel, met formal testing requirements for identifying a subset of relevant species of bacteria. However, BD prioritizes projects using criteria that are not limited to technical factors.

"We're disappointed by BD's decision not to exercise its exclusive option," Accelr8 President David Howson said in a statement.

"Nevertheless, we made substantial advances and gained strong supporting technical evidence in the project, including integrated testing using patient specimens," Howson added. "We will continue discussions with other prospective collaborators."

Accelr8 said that BACcel is the only technology supported by published data to provide same-day analysis of all significant highly drug-resistant bacteria and their particular resistance mechanisms.

In Friday afternoon trade on the American Stock Exchange, shares of Accelr8 were down 29 percent at $1.80.

The Scan

Cell Signaling Pathway Identified as Metastasis Suppressor

A new study in Nature homes in on the STING pathway as a suppressor of metastasis in a mouse model of lung cancer.

Using Bees to Gain Insights into Urban Microbiomes

As bees buzz around, they pick up debris that provides insight into the metagenome of their surroundings, researchers report in Environmental Microbiome.

Age, Genetic Risk Tied to Blood Lipid Changes in New Study

A study appearing in JAMA Network Open suggests strategies to address high lipid levels should focus on individuals with high genetic risk and at specific ages.

Study Examines Insights Gained by Adjunct Trio RNA Sequencing in Complex Pediatric Disease Cases

Researchers in AJHG explore the diagnostic utility of adding parent-child RNA-seq to genome sequencing in dozens of families with complex, undiagnosed genetic disease.